Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment

Reuters Staff  |  

(Reuters)—Sanofi SA and partner Regeneron Pharmaceuticals Inc. have started a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a treatment for the coronavirus, the companies said on Monday.

Enrolments for the mid-to-late stage trial will begin immediately, and the companies anticipate the trial will test up to 400 patients.

ADVERTISEMENT
SCROLL TO CONTINUE

Sarilumab is an infection-fighting protein known as monoclonal antibody.

Regeneron in February announced a partnership with the U.S. Department of Health and Human Services to develop a coronavirus treatment and had said it would focus on monoclonal antibodies.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Data on Arthritis Drug to Treat Coronavirus Could Come within Weeks

    (Reuters)—Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron’s chief scientific officer told Reuters. “We could be one to two weeks—at most a month or so—away from knowing…

    Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment

    (Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada…